3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
3
Brain Neoplasms
3
Astrocytoma
3
Oligodendroglioma
2
Gliosarcoma
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Neurofibromatosis 2
1
Melanoma
1
Macular Degeneration
1
Glioma
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
brolucizumab
1
aflibercept
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Macular Degeneration
×
aflibercept
×
CNS
×
Clear all
NCT03710564
2023-01-30
MERLIN
Novartis
Phase 3
Terminated
535 enrolled
14 charts